vezetés Fogazott zsolozsma abemaciclib overall survival A fején bosszantani Kezdő
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
ESMO-BC 2023: Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
Developments in Advanced Breast Cancer Treatment | EMJ Reviews
PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar
SABCS 2022: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
Update Shows Long-Term Survival Benefit with Abemaciclib Plus
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 - Rugo - 2021 -
SABCS 2022: Final overall survival analysis of Monarch 2 : A phase 3 trial of Abemaciclib plus Fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup